Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Cytokinetics (Nasdaq: CYTK) announced that company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 1:30 PM ET.
Rhea-AI Summary
Cytokinetics (Nasdaq: CYTK) announced that company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 1:30 PM ET.
According to Cytokinetics, the event will be webcast live and the replay will be archived on the company website for 90 days.
Details
News Market Reaction – CYTK
On Apr 7, the first trading day after this news, CYTK closed 0.83% above the previous close.
Data tracked by StockTitan Argus for the Apr 7 session.
Key Figures
- Conference edition
- 25th annual
- Needham Virtual Healthcare Conference
- Fireside chat time
- 1:30 PM ET
- Needham conference on April 13, 2026
- Webcast archive
- 90 days
- Replay availability on company website
- Year-end cash
- $1.22 billion
- Cash balance at end of 2025
- 2025 revenue
- $88.0 million
- Full-year 2025 revenue
- 2026 expense guidance
- $830–870 million
- 2026 GAAP R&D+SG&A guidance
- RSUs for sale
- 45,000 units
- Form 144 planned disposals by Robert Blum
- Insider sale proceeds
- $2,274,752.15
- Form 144 reported disposal of 36,601 shares
Historical Context
-
Inducement stock options and RSUs granted to new employees.
-
Four ACC 2026 presentations on MYQORZO clinical and ECG analyses.
-
Participation in multiple March healthcare investor events in Miami Beach.
-
Q4 2025 results, cash position, revenue and 2026 expense guidance.
-
European Commission approval of MYQORZO for symptomatic oHCM adults.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 1:30 PM Eastern Time.
Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is also being studied for the potential treatment of non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Disclaimer
Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.